Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMS | P04818 | 7/20 | 0.56 |
| ▸ | DHFR | P00374 | 7/20 | 0.56 |
| ▸ | GART | P22102 | 7/20 | 0.56 |
| ▸ | ATIC | P31939 | 2/20 | 0.56 |
| ▸ | FOLR2 | P14207 | 2/20 | 0.56 |
| ▸ | FOLR1 | P15328 | 2/20 | 0.56 |
| ▸ | SLC46A1 | Q96NT5 | 2/20 | 0.56 |
| ▸ | SHMT1 | P34896 | 1/20 | 0.56 |
| ▸ | SLC19A1 | P41440 | 1/20 | 0.56 |
| ▸ | FRK | P42685 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19623246 | 1.00 | TYMS (0.56) | TYMSDHFRGARTATICFOLR2 | |
| SCHEMBL23544600 | 0.93 | GART (0.65) | TYMSDHFRGARTATICFOLR2 | |
| SCHEMBL19623252 | 0.93 | GART (0.65) | TYMSDHFRGARTATICFOLR2 | |
| SCHEMBL1237946 | 0.91 | TYMS (0.49) | TYMSDHFRGARTATICFOLR2 | |
| SCHEMBL2285818 | 0.91 | TYMS (0.49) | TYMSDHFRGARTATICFOLR2 | |
| SCHEMBL371409 | 0.90 | DHFR (0.57) | TYMSDHFRGARTATICFOLR2 | |
| SCHEMBL27835031 | 0.90 | DHFR (0.57) | TYMSDHFRGARTATICFOLR2 | |
| SCHEMBL8855175 | 0.88 | TYMS (0.73) | TYMSDHFRGARTATICFOLR2 | |
| SCHEMBL8855178 | 0.88 | TYMS (0.73) | TYMSDHFRGARTATICFOLR2 | |
| SCHEMBL28544653 | 0.86 | TYMS (0.55) | TYMSDHFRGARTATICFOLR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130165654-A1 | PROCESSES FOR PREPARING PEMETREXED | DR. REDDY'S LABORATORIES, INC. (US) | 2013-06-27 | — | — | US | claimed |
| EP-2464650-A2 | PROCESSES FOR PREPARING PEMETREXED | Dr. Reddy's Laboratories, Ltd. (IN) | 2012-06-20 | — | — | EP | claimed |
| WO-2011019986-A2 | PROCESSES FOR PREPARING PEMETREXED | DR. REDDY'S LABORATORIES LTD. (IN) | 2011-02-17 | — | — | WO | claimed |
| US-20150259348-A1 | PROCESS FOR PREPARING PEMETREXED DI POTASSIUM AND ITS HYDRATES | SHILPA MEDICARE LIMITED (IN) | 2015-09-17 | — | — | US | disclosed |
| EP-2909208-A1 | PROCESS FOR PREPARING PEMETREXED DI POTASSIUM AND ITS HYDRATES | Shilpa Medicare Limited (IN) | 2015-08-26 | — | — | EP | disclosed |
| WO-2014060959-A1 | CRYSTALLINE PEMETREXED DIPOTASSIUM PROCESS | SHILPA MEDICARE LIMITED (IN) | 2014-04-24 | — | — | WO | disclosed |
| WO-2014060953-A1 | PROCESS FOR PREPARING PEMETREXED DI POTASSIUM AND ITS HYDRATES | SHILPA MEDICARE LIMITED (IN) | 2014-04-24 | — | — | WO | disclosed |
| EP-2675808-A2 | PROCESS FOR PEMETREXED DISODIUM | Hetero Research Foundation (IN) | 2013-12-25 | — | — | EP | disclosed |
| EP-2675808-A2 | PROCESS FOR PEMETREXED DISODIUM | Hetero Research Foundation (IN) | 2013-12-25 | — | — | EP | disclosed |
| US-20130165654-A1 | PROCESSES FOR PREPARING PEMETREXED | DR. REDDY'S LABORATORIES, INC. (US) | 2013-06-27 | — | — | US | disclosed |
| WO-2012111027-A2 | PROCESS FOR PEMETREXED DISODIUM | HETERO RESEARCH FOUNDATION (IN) | 2012-08-23 | — | — | WO | disclosed |
| WO-2012111027-A2 | PROCESS FOR PEMETREXED DISODIUM | HETERO RESEARCH FOUNDATION (IN) | 2012-08-23 | — | — | WO | disclosed |
| EP-2464650-A2 | PROCESSES FOR PREPARING PEMETREXED | Dr. Reddy's Laboratories, Ltd. (IN) | 2012-06-20 | — | — | EP | disclosed |
| WO-2011019986-A2 | PROCESSES FOR PREPARING PEMETREXED | DR. REDDY'S LABORATORIES LTD. (IN) | 2011-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150259348-A1 | PROCESS FOR PREPARING PEMETREXED DI POTASSIUM AND ITS HYDRATES | DPYD, KCNK5, KCNJ11 | TYMS 4/4885DHFR 62/4885GART 379/4885 |
| US-20130165654-A1 | PROCESSES FOR PREPARING PEMETREXED | TYMP, TYMS, DPYD | TYMS 2/4885DHFR 10/4885GART 144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.